首页> 外文期刊>The Scientist >Malaria, Science, and Social Responsibility
【24h】

Malaria, Science, and Social Responsibility

机译:疟疾,科学和社会责任

获取原文
获取原文并翻译 | 示例
           

摘要

A problem that has seemed intractable for decades may finally be cracking: How to create affordable drug therapies for people who don't offer pharmaceutical companies a commercial market? Jay Keasling, at the University of California, Berkeley; Amyris Biotechnologies, in Emeryville, Calif.; the Institute for OneWorld Health in San Francisco; and the Bill and Melinda Gates Foundation have formed a public-private partnership to produce a genetically engineered version of one of the world's most effective malaria drugs. Such partnerships aren't new. The International AIDS Vaccine Initiative in New York and the Geneva-based Global Fund to Fight AIDS, Tuberculosis, and Malaria work in a similar way. But the latest collaboration puts a new twist on the idea. A multimillion-dollar grant will be used to pursue an unproven technology that, if it works, will not only be useful against malaria and other ailments, but also will be given to the world for free.
机译:几十年来似乎棘手的问题可能最终会解决:如何为那些不向制药公司提供商业市场的人们创造负担得起的药物疗法?加州大学伯克利分校的Jay Keasling;位于加利福尼亚州埃默里维尔的Amyris生物技术公司;旧金山的寰宇一家卫生研究所;比尔(Bill)和梅琳达·盖茨(Melinda Gates)基金会已经建立了公私合作伙伴关系,以生产世界上最有效的疟疾药物之一的基因工程版本。这样的伙伴关系并不是新的。纽约的国际艾滋病疫苗倡议和总部位于日内瓦的全球抗击艾滋病,结核病和疟疾基金以类似的方式开展工作。但是最新的合作给这个想法带来了新的变化。数百万美元的赠款将用于追求一种未经证实的技术,如果该技术可行,它将不仅对付疟疾和其他疾病有用,而且还将免费提供给全世界。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号